Business
NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in China
Publication in key market advances NewcelX's global IP strategy across Asia and supports the Company's expanding position in neurology and metabolic
About this update from Newcelx Ltd.
[{"type":"text","content":"Publication in key market advances NewcelX's global IP strategy across Asia and supports the Company's expanding position in neurology and metabolic diseasesZURICH, Dec. 11, 2025 /PRNewswire/ -- NewcelX Ltd. (Nasdaq: NCEL), a next-generation biotechnology company developing advanced cell-therapy and neuroscience-driven therapeutics, today announced the publication of a major international patent application in China covering a new class of quinazoline, benzothiazine, and benzoxazine derivatives (DOXA) for the treatment of neurological diseases.\n \n \n \n \n \n \n \nThis publication marks an important expansion of the Company's proprietary small-molecule portfolio, supporting NewcelX's strategy of advancing therapeutic innovation across sleep-wake disorders, neurodegeneration, and metabolic disease. This represents a meaningful expansion of NewcelX's proprietary small-molecule technology estate as the Company advances its innovation strategy across cell therapy, regenerative medicine, and CNS drug development.Key Patent InformationPriority: Europe Patent Application No. 22307075.6, filed December 30, 2022PCT Filing: International Patent Application No. PCT/2023800948590, filed December 29, 2023China Publication: CN 120981232 A, published November 18, 2025Title: Quinazoline, Benzothiazine or Benzoxazine Derivatives for Neurological DiseasesInternal Reference: B386678CN / D43080\"The publication of this patent application in China is an important step in expanding the global reach of our IP portfolio,\" said Ronen Twito, Chief Executive Officer and Executive Chairman of NewcelX. \"It strengthens the foundation of our DOXA small-molecule platform and supports our long-term strategy to build a diversified therapeutic pipeline in neurology.\"\"This patent marks a key milestone for the DOXA program,\" said Dr. Eric Konofal, Head of the DOXA Program. \"These compounds reflect years of translational work in neuropharmacology and medicinal chemistry aimed at developing first- or best-in-class treatments for major CNS disorders, from ALS to narcolepsy.\"The patent covers a broad family of compounds with potential applications in multiple CNS-related conditions, including narcolepsy, where dysregulation of orexin signalling plays a central role. DOXA compounds are designed to modulate pathways implicated in sleep-wake regulation, neuroinfl...